2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia
4
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Leukemia, T-Cell
1
Leukemia, Lymphoid
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
63
fludarabine phosphate
40
Peripheral Blood Stem Cell Transplantation
34
Vincristine
30
Methotrexate
30
Etoposide
29
Cytarabine
28
Dexamethasone
27
Whole-Body Irradiation
25
Doxorubicin
25
Mycophenolic Acid
23
Prednisone
22
Tacrolimus
21
Filgrastim
21
Busulfan
19
Antilymphocyte Serum
18
venetoclax
17
nelarabine
17
Cyclosporine
17
Calcium Dobesilate
17
merphos
15
Rituximab
14
Radiotherapy
14
Methylprednisolone
13
Bortezomib
13
pegaspargase
12
dexamethasone acetate
11
dexamethasone 21-phosphate
11
Melphalan
11
prednylidene
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
forodesine
×
Clear all
NCT00742495
2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2
Terminated
2 enrolled